Necitumumab, an anti-EGFR mAb, was combined with pembrolizumab in 64 stage IV NSCLC patients who had progressed after platinum-based doublet, irrespective of PD-L1 expression and histology. The gene discussed is CD274; the disease is non-small cell lung carcinoma.